Clinical trial NCT02182349: Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers
Official title: Metabolism and Pharmacokinetics of a Single Dose of 240 mg [14C]-BI 201335 Given as Oral Solution to Healthy Male Volunteers at Steady State of BI 201335 NA Maintained With Oral Capsules of 240 mg BI 201335, a Phase I, Single-arm, Open-label Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-07-08
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study to determine the pharmacokinetics (PK) of BI 201335 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of \[14C\]-BI 201335 at steady state.


Eligibility criteria: Inclusion Criteria:

* Healthy males according to a complete medical history, including a physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG (electrocardiogram), and clinical laboratory tests
* Age 18 to 55 years, inclusive
* Body mass index 18.5 to 29.9 kg/m2, inclusive
* Nonsmoker
* Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion Criteria:

* Any finding in the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
* Any evidence of a clinically relevant concomitant disease
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hormonal, psychiatric or neurological disorders (including all forms of epilepsy)
* Surgery of the gastrointestinal tract (except appendectomy)
* History of relevant orthostatic hypotension, fainting spells or blackouts
* Subjects with Gilbert's Syndrome
* Chronic or relevant acute infections
* History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
* Intake of drugs with a long half-life (\>24 hours) within one month prior to administration of the trial drug
* Use of prescription medication, over-the-counter drugs or herbal preparations within 14 days prior to administration of the trial drug
* Participation in another trial with an investigational drug within two months prior to administration of the trial drug or during the trial
* History or evidence of habitual tobacco or nicotine use within six months prior to administration of the trial drug
* Alcohol abuse (more than 2 ounces of alcohol/day)
* Drug abuse in opinion of investigator
* Blood donation (more than 100 mL within four weeks prior to administration of trial drug or during the trial)
* Excessive physical activity within five days prior to administration of trial drug
* Any laboratory value outside the reference range that is of clinical relevance
* Inability to comply with dietary regimen of trial centre
* marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms)
* Male subjects must agree to minimise the risk of female partners becoming pregnant from the dosing day until three months after the completion of the study. Acceptable methods of contraception for male volunteers include a vasectomy no less than three months prior to dosing, barrier contraception, or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intrauterine device, tubal ligation, hormonal contraceptive for at least two months, or diaphragm with spermicide
* Participation in more than one other radiolabelled investigational drug trial within one year prior to administration of the trial drug. The previous radiolabelled trial drug must have been received more than six months prior to administration of the trial drug for this study, and the total exposure from this study and the previous study will be within the recommended levels considered safe (e.g., less than 5000 mrem whole body annual exposure)
* Irregular defecation pattern (less than one bowel movement a day)

Primary outcomes:
measure: Individual concentration-time profiles of [14C]-radioactivity in whole blood, plasma, saliva, urine, and faeces
timeFrame: up to 28 days
measure: Individual concentration-time profiles of BI 201335 ZW in plasma and urine
timeFrame: up to 28 days
measure: Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces
timeFrame: up to 28 days
measure: Elucidation of metabolite structures and identification of major metabolites in urine, faeces, and plasma in comparison with various animal species
timeFrame: up to 28 days
measure: Cblood cell/Cplasma ratio of [14C]-radioactivity
timeFrame: up to 28 days
measure: Measurement of the plasma protein binding of total [14C]-radioactivity in human plasma samples ex vivo
timeFrame: up to day 28
measure: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
timeFrame: up to day 28
measure: tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)
timeFrame: up to day 28
measure: Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
timeFrame: up to day 28
measure: AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
timeFrame: up to day 28
measure: λz,ss (terminal rate constant of the analyte in plasma at steady state)
timeFrame: up to day 28
measure: t1/2,ss (terminal half-life of the analyte in plasma at steady state)
timeFrame: up to day 28
measure: MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)
timeFrame: up to day 28
measure: CL/F,ss (apparent clearance of the analyte in the plasma at steady state following multiple oral dose administration)
timeFrame: up to day 28
measure: Vz/F,ss (apparent volume of distribution of the analyte during the terminal phase λz at steady state following oral administration)
timeFrame: up to day 28
measure: Ae,urine,0-tz,ss (amount of analyte that is eliminated in urine at steady state from the time point 0 to time point tz)
timeFrame: up to day 28
measure: fe,urine,t1-t2,ss (fraction of the analyte in % of dose that is eliminated in urine at steady state from the time point 0 to time point tz)
timeFrame: up to day 28
measure: Ae,feces,t1-t2,ss (fraction of the analyte that is eliminated in faeces at steady state from time point 0 to time point tz)
timeFrame: up to day 28
measure: fe,feces,0-tz,ss (fraction of the analyte eliminated in faeces at steady state from time point 0 to time point tz)
timeFrame: up to day 28
measure: CLR,t1-t2,ss (renal clearance of the analyte at steady state from the time point 0 to time point tz)
timeFrame: up to day 28
Secondary outcomes:
measure: Number of patients with abnormal findings in physical examination
timeFrame: Baseline and day 28
measure: Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)
timeFrame: Baseline, day 1, 10, 16 and 28
measure: Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)
timeFrame: Baseline, day 1, 10, 16 and 28
measure: Number of patients with clinically significant changes in clinical laboratory tests (haematology, clinical chemistry, urinalysis)
timeFrame: Baseline, day 10 and 28
measure: Number of patients with adverse events
timeFrame: up to 28 days
measure: Assessment of tolerability on a 4-point scale by the investigator
timeFrame: Day 28
Other outcomes:
Locations:
Study officials:
References: